SeekingAlpha · Jul 24, 2026
Attovia Therapeutics Begins IPO Effort On Promising Early Trials
Attovia Therapeutics eyes a U.S. IPO to fund ATTO-1310 and its immune disease pipeline. Read the full analysis here.

NYSE · ATTO
Industrials · Specialty Business Services
$19.18
Up+$0.68 (+3.55%)
Updated Aug 14, 2026, 11:03 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 7 trading sessions · Daily adjusted prices
ATTO closed at $19.18 after 7 trading sessions, down 12.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $18.06 | $19.36 | $17.965 | $19.18 | 406.53K |
| Aug 12, 2026 | $18.68 | $19.30 | $16.1501 | $18.06 | 603.88K |
| Aug 11, 2026 | $19.84 | $20.495 | $18.65 | $18.65 | 475.62K |
| Aug 10, 2026 | $20.17 | $20.17 | $18.50 | $19.84 | 376.6K |
| Aug 7, 2026 | $20.11 | $20.94 | $18.64 | $20.17 | 237.91K |
| Aug 6, 2026 | $22.05 | $22.05 | $19.63 | $20.38 | 413.25K |
| Aug 5, 2026 | $21.00 | $22.79 | $20.21 | $21.90 | 4.91M |
The latest Smart Investors Daily articles mentioning ATTO.
ATTO research
Company profile and research snapshot.
Atento S.A., together with its subsidiaries, provides customer relationship management business process outsourcing services and solutions in Brazil, the Americas, Europe, the Middle East, and Africa. It offers a range of front and back-end services, including sales, customer care, technical support, collections, and back office. The company serves clients primarily in the telecommunications, financial services, consumer goods, retail, public administration, healthcare, travel, transportation, logistics, and technology and media sectors. It provides its services and solutions through digital channels, which include SMS, email, chats, social media and apps, and others, as well as through voice. The company was formerly known as Atento Floatco S.A. Atento S.A. was founded in 1999 and is based in Luxembourg.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 15, 2022 | Barrington Research | Outperform | — |
| Jul 5, 2022 | Goldman Sachs | Neutral | — |
| Sep 21, 2021 | Goldman Sachs | Neutral | — |
| Apr 30, 2020 | Goldman Sachs | Sell | — |
| Jun 5, 2019 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
SeekingAlpha · Jul 24, 2026
Attovia Therapeutics eyes a U.S. IPO to fund ATTO-1310 and its immune disease pipeline. Read the full analysis here.
PennyStocks · May 30, 2023
AI penny stocks to watch this week. The post Penny Stocks To Buy? 3 AI Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research · Dec 15, 2022
Atento (ATTO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks Investment Research · Nov 29, 2022
Atento (ATTO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning ATTO.
No results
No recent SID articles mention ATTO.